The bill, sponsored by Sen. Ed Hernández (D), would also require drug manufacturers to provide notice when a new drug will cost $10,000 or more per year, or during a course of treatment, according to the report.
Sen. Hernández cited examples of such instances, such as drugs for hepatitis, which can cost $84,000 for a course of treatment. He also noted the price of generic antibiotics increased by 2,000 percent in one year.
“Shining a light for the first time is having the greatest impact on our healthcare system,” Sen. Hernández said, according to the report. “Members, this is not price control. This is transparency.”
The bill was approved on a vote of 24 to 8, according to the report.
More articles on legal and regulatory issues:
Memphis VA cited by OSHA after body tissue found in drain
Consulting firm president gets 5-year prison term for role in kickback scheme
NJ hospital to pay $450k for allegedly billing Medicare for unnecessary heart procedures
